Durvalumab plus gemcitabine-cisplatin versus S-1 plus gemcitabine-cisplatin in advanced biliary tract cancer: a comparative study
Authors:
- T. SatakeTST. Satake
- M. SasakiMSM. Sasaki
- H. ImaokaHIH. Imaoka
- S. TaroSTS. Taro
- K. InoueKIK. Inoue
- T. TairaTTT. Taira
- G. IgarashiGIG. Igarashi
- M. AmisakiMAM. Amisaki
- H. TakahashiHTH. Takahashi
- S. MitsunagaSMS. Mitsunaga
- M. IkedaMIM. Ikeda
Open Access
- 20 November 2025
- journal article
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 10
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Guardant Health
- Ono Pharmaceutical
- Chugai Pharmaceutical
This publication has 31 references indexed in Scilit:
- Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical dataCancer Immunology, Immunotherapy, 2024
- Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohortUnited European Gastroenterology Journal, 2024
- Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers explorationCancer Immunology, Immunotherapy, 2024
- Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancersSurgery Today, 2024
- Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter StudyTargeted Oncology, 2024
- Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus DurvalumabTargeted Oncology, 2024
- Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathwayClinical and Translational Medicine, 2023
- Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)Journal of Hepato-Biliary-Pancreatic Sciences, 2022
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerJAMA Oncology, 2020
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studiesInternational Journal of Cancer, 2020